Hepatic impairment did not have any influence on the exposure of semaglutide. The pharmacokinetics of semaglutide were being evaluated in clients with distinctive degrees of hepatic impairment (mild, average, severe) in comparison with subjects with typical hepatic functionality within a review with a single-dose of 0.five mg semaglutide.The maximu